Literature DB >> 33539010

Protein Kinase-Mediated Decision Between the Life and Death.

Atilla Engin1.   

Abstract

Protein kinases are intracellular signaling enzymes that catalyze the phosphorylation of specific residues in their target substrate proteins. They play important role for regulation of life and death decisions. The complexity of the relationship between death receptors and protein kinases' cell death decision-making mechanisms create many difficulties in the treatment of various diseases. The most of fifteen different cell death pathways, which are reported by Nomenclature Committee on Cell Death (NCCD) are protein kinase signal transduction-mediated negative or positive selections. Tumor necrosis factor (TNF) as a main player of death pathways is a dual-functioning molecule in that it can promote both cell survival or cell death. All apoptotic and necrotic signal transductions are conveyed through death domain-containing death receptors, which are expressed on the surface of nearly all human cells. In humans, eight members of the death receptor family have been identified. While the interaction of TNF with TNF Receptor 1 (TNFR1) activates various signal transduction pathways, different death receptors activate three main signal transduction pathways: nuclear factor kappa B (NF-ĸB)-mediated differentiation or pro-inflammatory cytokine synthesis, mitogen-activated protein kinase (MAPK)-mediated stress response and caspase-mediated apoptosis. The link between the NF-ĸB and the c-Jun NH2-terminal kinase (JNK) pathways comprise another check-point to regulate cell death. TNF-α also promotes the "receptor-interacting serine/threonine protein kinase 1" (RIPK1)/RIPK3/ mixed lineage kinase domain-like pseudokinase (MLKL)-dependent necrosis. Thus, necrosome is mainly comprised of MLKL, RIPK3 and, in some cases, RIPK1. In fact, RIPK1 is at the crossroad between life and death, downstream of various receptors as a regulator of endoplasmic reticulum stress-induced death. TNFR1 signaling complex (TNF-RSC), which contains multiple kinase activities, promotes phosphorylation of transforming growth factor β-activated kinase 1 (TAK1), inhibitor of nuclear transcription factor κB (IκB) kinase (IKK) α/IKKβ, IκBα, and NF-κB. IKKs affect cell-survival pathways in NF-κB-independent manner. Toll-like receptor (TLR) stimulation triggers various signaling pathways dependent on myeloid differentiation factor-88 (MyD88), Interleukin-1 receptor (IL-1R)-associated kinase (IRAK1), IRAK2 and IRAK4, lead to post-translational activation of nucleotide and oligomerization domain (NLRP3). Thereby, cell fate decisions following TLR signaling is parallel with death receptor signaling. Inhibition of IKKα/IKKβ or its upstream activators sensitize cells to death by inducing RIPK1-dependent apoptosis or necroptosis. During apoptosis, several kinases of the NF-κB pathway, including IKK1 and NF-κB essential modulator (NEMO), are cleaved by cellular caspases. This event can terminate the NF-κB-derived survival signals. In both canonical and non-canonical pathways, IKK is key to NF-κB activation. Whereas, the activation process of IKK, the functions of NEMO ubiquitination, IKK-related non-canonical pathway and the nuclear transportation of NEMO and functions of IKKα are still debated in cell death. In addition, cluster of differentiation 95 (CD95)-mediated non-apoptotic signaling and CD95- death-inducing signaling complex (DISC) interactions are waiting for clarification.

Entities:  

Keywords:  E3 ligase linear ubiquitin chain assembly complex (LUBAC); Fas-associated death domain (FADD); Nuclear factor kappa B essential modulator (NEMO); Shank-associated RH domain-interacting protein (SHARPIN); Tumor necrosis factor receptor associated-protein with death domain (TRADD); Tumor necrosis factor receptor-associated factor 2 (TRAF); Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL); cellular FADD-like interleukin-1-converting enzyme (FLICE) inhibitory protein (cFLIP); mitogen-activated protein (MAP) kinase mitogen-activated protein kinase (MAPK); receptor-interacting serine/threonine protein kinase (RIPK)

Mesh:

Substances:

Year:  2021        PMID: 33539010     DOI: 10.1007/978-3-030-49844-3_1

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  231 in total

Review 1.  The Ras/MAPK cascade and the control of positive selection.

Authors:  José Alberola-Ila; Gabriela Hernández-Hoyos
Journal:  Immunol Rev       Date:  2003-02       Impact factor: 12.988

2.  cIAP1 and cIAP2 facilitate cancer cell survival by functioning as E3 ligases that promote RIP1 ubiquitination.

Authors:  Mathieu J M Bertrand; Snezana Milutinovic; Kathleen M Dickson; Wai Chi Ho; Alain Boudreault; Jon Durkin; John W Gillard; James B Jaquith; Stephen J Morris; Philip A Barker
Journal:  Mol Cell       Date:  2008-06-20       Impact factor: 17.970

Review 3.  Nuclear export of the stress-activated protein kinase p38 mediated by its substrate MAPKAP kinase-2.

Authors:  R Ben-Levy; S Hooper; R Wilson; H F Paterson; C J Marshall
Journal:  Curr Biol       Date:  1998-09-24       Impact factor: 10.834

4.  NF-kappa B: ten years after.

Authors:  P A Baeuerle; D Baltimore
Journal:  Cell       Date:  1996-10-04       Impact factor: 41.582

5.  The Nuclear Translocation of ERK.

Authors:  Denise A Berti; Rony Seger
Journal:  Methods Mol Biol       Date:  2017

6.  Interleukin-10 activates Toll-like receptor 4 and requires MyD88 for cardiomyocyte survival.

Authors:  Ashim K Bagchi; Anita Sharma; Sanjiv Dhingra; Ana R Lehenbauer Ludke; Abd Al-Rahman Al-Shudiefat; Pawan K Singal
Journal:  Cytokine       Date:  2012-11-08       Impact factor: 3.861

7.  Cutting edge: NF-kappaB activating pattern recognition and cytokine receptors license NLRP3 inflammasome activation by regulating NLRP3 expression.

Authors:  Franz G Bauernfeind; Gabor Horvath; Andrea Stutz; Emad S Alnemri; Kelly MacDonald; David Speert; Teresa Fernandes-Alnemri; Jianghong Wu; Brian G Monks; Katherine A Fitzgerald; Veit Hornung; Eicke Latz
Journal:  J Immunol       Date:  2009-07-01       Impact factor: 5.422

8.  MAP kinase phosphatase activity sets the threshold for thymocyte positive selection.

Authors:  Matthew L Bettini; Gilbert J Kersh
Journal:  Proc Natl Acad Sci U S A       Date:  2007-09-27       Impact factor: 11.205

9.  Positive and negative selection invoke distinct signaling pathways.

Authors:  J Alberola-Ila; K A Hogquist; K A Swan; M J Bevan; R M Perlmutter
Journal:  J Exp Med       Date:  1996-07-01       Impact factor: 14.307

10.  Distinct Activation Mechanisms of NF-κB Regulator Inhibitor of NF-κB Kinase (IKK) by Isoforms of the Cell Death Regulator Cellular FLICE-like Inhibitory Protein (cFLIP).

Authors:  Mehdi Baratchian; Christopher A Davis; Akira Shimizu; David Escors; Claire Bagnéris; Tracey Barrett; Mary K Collins
Journal:  J Biol Chem       Date:  2016-02-10       Impact factor: 5.157

View more
  4 in total

1.  Impact of FasL Stimulation on Sclerostin Expression and Osteogenic Profile in IDG-SW3 Osteocytes.

Authors:  Adela Kratochvilova; Alice Ramesova; Barbora Vesela; Eva Svandova; Herve Lesot; Reinhard Gruber; Eva Matalova
Journal:  Biology (Basel)       Date:  2021-08-07

2.  Comparative Proteomics of Coxiella like Endosymbionts (CLEs) in the Symbiotic Organs of Rhipicephalus sanguineus Ticks.

Authors:  Balasubramanian Cibichakravarthy; Juan A Oses-Prieto; Michael Ben-Yosef; Alma L Burlingame; Timothy L Karr; Yuval Gottlieb
Journal:  Microbiol Spectr       Date:  2022-01-12

3.  Ameliorative effects of epigallocatechin-3-gallate nanoparticles on 2,4-dinitrochlorobenzene induced atopic dermatitis: A potential mechanism of inflammation-related necroptosis.

Authors:  Mengguo Han; Xue Wang; Jian Wang; Dongcen Lang; Xiaohua Xia; Yongfang Jia; Ying Chen
Journal:  Front Nutr       Date:  2022-08-09

4.  The neuroprotective effects of melatonin against diabetic neuropathy: A systematic review of non-clinical studies.

Authors:  Asieh Hosseini; Mahedeh Samadi; Maryam Baeeri; Mahban Rahimifard; Hamed Haghi-Aminjan
Journal:  Front Pharmacol       Date:  2022-08-31       Impact factor: 5.988

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.